Superworth

Iradimed price to free cash flow IRMD

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026
43.7×
10-year median
46.2×
Against its 10-year history
45th
percentile: 0 is its lowest day, 100 its highest
10-year range
9.7× to 110×
Peer median
17.6×

Iradimed's price to free cash flow is 43.7× as of Oct 23, 2026.

That is below its ten-year median of 46.2×, close to the middle of its last ten years.

Over that time it ranged from 9.7× in Feb 2017 to 110× in Dec 2023.

The median for 10 medical instruments and supplies stocks of a similar size is 17.6×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far43.7×41.8×89.3×
202584.0×36.0×84.0×
202438.9×34.4×106×
2023110×38.7×110×
202236.6×35.0×61.8×
202157.6×40.5×82.3×
202041.4×19.4×45.3×
201929.6×26.4×62.0×
201850.9×40.9×73.3×
201747.7×9.7×47.7×
201613.1×10.8×69.6×
201579.4×73.5×136×

Against its peers

Companies in Medical - Instruments & Supplies nearest Iradimed's size, closest first, today.

CompanyPrice to free cash flow
IRMDIradimed43.7×
STAAStaar Surgicaln/m
BVSBioventus13.3×
CDRECadre16.4×
EYENational Vision30.1×
MOVMovado9.8×
LMATLemaitre Vascular26.2×
INSPInspire Medical Systems17.6×
MDXGMimedxn/m
TCMDTactile Systems Technology20.0×
UFPTUFP Technologiesn/m
Peer median17.6×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Iradimed

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.